This comment period is important for biosimilar stakeholders because the Trump administration's plan has addressed specific efforts being made by the FDA and HHS to improve biosimilar development, approval, education, and access.
In his speech last Friday, President Trump unveiled his blueprint for reducing the price of drugs for American patients. In a notice published today on the Federal Register, HHS has announced that it is seeking comment on the blueprint to help shape future policy development and agency action. This comment period is important for biosimilar stakeholders because the plan has addressed specific efforts being made by the FDA and HHS to improve biosimilar development, approval, education, and access.
Through the plan, the FDA is prioritizing efforts to improve the efficiency of the biosimilar and interchangeable product development and approval process by working to identify areas where additional information or development tools may facilitate increased growth of biosimilars. Specifically, the agency has asked industry what types of resources or tools they would find most effective in reducing development costs.
Additionally, HHS is calling on the FDA to improve the Purple Book, where the FDA publishes information about licensed biological products. HHS is requesting opinions about how the Purple Book could be more useful to healthcare professionals, patients, manufacturers, or other stakeholders.
In order to improve the education of providers and patients about biosimilars, the FDA intends to continue to build on the momentum of prior education efforts. Previous actions included the launch of its Biosimilars Education and Outreach campaign in 2017, as well as graphics, fact sheets, and other resources available on its website.
In addition, FDA Commissioner Scott Gottlieb, MD, has also recently hinted that the FDA could publish the names of pharmaceutical companies that have been accused of withholding drug samples from generic or biosimilar developers.
Finally, HHS and the FDA have also recognized that thus far, no drug manufacturer has applied for or developed a biosimilar with the intention of seeking an “interchangeable” designation. To address this, HHS is requesting comment about how the designation could be improved, and what effects would the change have on the prescribing, dispensing, and coverage of biosimilar and interchangeable products. The FDA has not yet issued final guidance on demonstrating interchangeability of a biosimilar with its reference, though draft guidance has been released.
Stakeholders and interested parties may submit comments from today until July 16, 2018.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Cordavis Report Outlines Strategies for Biosimilar Development, Access in the US Health Care Market
May 8th 2024Cordavis, a CVS Healthspire company, released a report detailing the current hurdles faced in developing and commercializing biosimilars in the US and highlighting efforts by the organization to enhance access and affordability for these products.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
May 2nd 2024Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.